Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Quote. Delayed Nasdaq - 10/30 04:00:00 pm
58.15 USD   -0.65%
10/29GLOBAL MARKETS LIVE: Big names today
10/29GILEAD SCIENCES : Announces Fourth Quarter 2020 Dividend
AQ
10/29GILEAD SCIENCES : Announces Third Quarter 2020 Financial Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Tech leads crisis-driven M&A boom with $350 billion deal rush

share with twitter share with LinkedIn share with facebook
09/15/2020 | 02:31am EDT

Sept 14 (Reuters) - Global M&A volumes are approaching $2 trillion for 2020, with technology making up almost a fifth of the total after mammoth deals such as SoftBank's $40 billion sale of chipmaker Arm.

Dealmaking has stepped up a gear in September, with Nvidia Corp on Monday announcing the purchase of Arm from Japan's SoftBank.

Others are coming thick and fast, with Verizon buying Mexican mobile phones provider Tracfone for $6.25 billion and Gilead Sciences to acquire biotech firm Immunomedics for $21 billion.

Such waves are characteristic after downturns, but Refinitiv data shows 2020's $1.97 trillion total of deals announced so far exceeds $1.26 trillion and $1.6 trillion during the same period in 2009 and 2010 respectively, after the 2008 financial crisis.

"Coming out of recession, there's usually a bit of catch-up to do and the cost of capital tends to be cheap," Graham Secker, chief European equity strategist at Morgan Stanley, said.

Tech firms comprised 17.8% of the total at $351.4 billion, the highest level since the dotcom boom of 2000, while financial services were in second place with a deal value of $283.8 billion or 14% of the total, Refinitiv said.

Tech's dominance, the data showed 5,966 deals targeting tech so far this year out of a total of just over 30,000, reflects the wider impact the coronavirus crisis has had.

The en masse switch by people stuck at home to internet-powered platforms for shopping, working, schooling, medical consultations and communication has sparked speculation that some of these shifts are permanent.

"Because of the changes that will come on back of this, companies will be thinking of whether they have the right business structures. There is a greater risk of a structural change in consumer behaviour than after previous recessions," Secker at Morgan Stanley said.

(Reporting by Sujata Rao; Additional reporting by Rachel Armstrong; Editing by Alexander Smith)


Stocks mentioned in the article
ChangeLast1st jan.
AMÉRICA MÓVIL, S.A.B. DE C.V. 0.23% 12.91 End-of-day quote.-14.50%
GILEAD SCIENCES, INC. -0.65% 58.15 Delayed Quote.-10.51%
IMMUNOMEDICS, INC. 0.05% 87.86 End-of-day quote.315.22%
MORGAN STANLEY 0.06% 48.15 Delayed Quote.-5.81%
NVIDIA CORPORATION -3.76% 501.36 Delayed Quote.113.07%
SOFTBANK GROUP CORP. -1.65% 6793 End-of-day quote.42.83%
VERIZON COMMUNICATIONS INC. 0.41% 56.99 Delayed Quote.-7.18%
share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
10/29GLOBAL MARKETS LIVE: Big names today
10/29GILEAD SCIENCES : Announces Fourth Quarter 2020 Dividend
AQ
10/29GILEAD SCIENCES : Announces Third Quarter 2020 Financial Results
AQ
10/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/29GILEAD SCIENCES : cuts 2020 sales outlook as COVID-19 drug remdesivir falls shor..
RE
10/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/28Gilead Quarterly Revenue Rises on Remdesivir Sales -- Update
DJ
10/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 23 690 M - -
Net income 2020 424 M - -
Net Debt 2020 19 768 M - -
P/E ratio 2020 107x
Yield 2020 4,63%
Capitalization 72 904 M 72 904 M -
EV / Sales 2020 3,91x
EV / Sales 2021 3,66x
Nbr of Employees 11 800
Free-Float 99,7%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 74,21 $
Last Close Price 58,15 $
Spread / Highest target 80,6%
Spread / Average Target 27,6%
Spread / Lowest Target -0,26%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-10.51%72 904
REGENERON PHARMACEUTICALS44.76%57 199
VERTEX PHARMACEUTICALS-4.84%54 210
WUXI APPTEC CO., LTD.71.31%40 863
BEIGENE, LTD.78.89%26 872
GENMAB A/S43.71%21 783